| SrNo | Topic | Description |
| 1 | Protocol-I for Indigenous product development, manufacture
and marketing of pharmaceutical products derived from LMOs but the end product
is not a LMO.
(Risk group I and II) |
- Information to RCGM to carry out research involving GMOs/LMOs for development of
r-DNA products for healthcare and industrial use. (
PDF Format ) (
Word Format )
- Application to RCGM to conduct preclinical and/or safety studies of rDNA
products developed using GMOs/LMOs for healthcare, industrial or any other use.
(
PDF Format ) (
Word Format )
|
| 2 | Protocol-I for Indigenous product development, manufacture
and marketing of pharmaceutical products derived from LMOs but the end product
is not a LMO.
(Risk group III and above) |
- Same as above in addition with
Recommendation of GMOs/LMOs to GEAC for agriculture and environment use. (
PDF Format ) (
Word Format )
|
| 3 |
Protocol-II for
Indigenous product development, manufacture and marketing pharmaceutical
products where the end product is a LMO | Same as above |
| 4 | Protocol-III for Import and marketing of Pharma Products in
Finished Formulations for Import and marketing of Pharma Products in
Finished Formulations where the End Product is a LMO |
|
| 5 | Protocol – IV
Import and marketing of Pharma Products in Bulk for making Finished Formulation
where the End Product is a LMO | |
| 6 |
Protocol – V Import and marketing of Pharma Products derived from LMOs in
bulk and/or Finished Formulations where the end product is not a LMO |
|
| 7 |
Step wise procedures for the development of Transgenic crops |
|
